Sarepta Therapeutics (SRPT) Interest Expenses (2010 - 2026)

Sarepta Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Interest Expenses rose 4.56% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 4.56% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 160.43% from the prior year.
• Interest Expenses climbed to $1.0 billion in Q1 2026 per SRPT's latest filing, from -$40.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $1.1 billion in Q2 2025 and bottomed at -$94.5 million in Q4 2022.
• The 5-year median for Interest Expenses is $14.7 million (2022), against an average of $298.6 million.
• Across the five-year window, Interest Expenses tumbled 946.73% in 2022 and soared 23323.01% in 2025, its largest moves.
• Year by year, Interest Expenses stood at -$94.5 million in 2022, then surged by 58.97% to -$38.8 million in 2023, then soared by 149.78% to $19.3 million in 2024, then tumbled by 307.36% to -$40.0 million in 2025, then soared by 2684.17% to $1.0 billion in 2026.
• Per Business Quant, the three latest SRPT Interest Expenses figures stand at $1.0 billion (Q1 2026), -$40.0 million (Q4 2025), and $1.1 billion (Q3 2025).